How Treating Patients Earlier with Statins and Ezetimibe Prevents Heart Attacks
Cardiovascular disease remains the leading cause of death globally, with heart attacks posing a significant risk. Treating patients earlier with statins and ezetimibe could drastically reduce heart attacks, strokes, and deaths, according to a new study.
The Importance of Early Treatment
Treating patients earlier with statins and ezetimibe stabilizes LDL (“bad”) cholesterol levels, reducing the risk of recurring cardiovascular events. Key findings include:
Patients who received combination therapy within 12 weeks of a heart attack had better outcomes.
Early treatment lowered cholesterol to target levels faster.
Fewer heart attacks, strokes, and deaths were recorded in early-treated patients.
Why Current Guidelines Need Updating
Currently, most patients receive only statins post-heart attack. However, research shows:
Statins alone often fail to reach optimal cholesterol levels.
Adding ezetimibe significantly improves results.
Delayed or no add-on treatment increases risks unnecessarily.
Global Impact of Early Combination Therapy
If implemented worldwide, treating patients earlier with statins and ezetimibe could:
✔ Prevent 133 heart attacks per 10,000 patients in three years.
✔ Reduce healthcare costs by avoiding preventable complications.
✔ Save thousands of lives annually.
Treating Patients Earlier with Statins and Ezetimibe: FAQs
Q: How soon should patients start combination therapy after a heart attack?
A: Ideally within 12 weeks for the best outcomes.
Q: Why is ezetimibe added to statins?
A: Statins alone often don’t lower LDL enough; ezetimibe enhances cholesterol reduction.
Q: What are the long-term benefits?
A: Lower risk of recurrent heart attacks, strokes, and death.
Conclusion
Treating patients earlier with statins and ezetimibe saves lives and prevents cardiovascular events.
Also Read: New RNA-Based Blood Test Detects Parkinson’s Disease Early
About The Author
